Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Greenwich LifeSciences (GLSI) Share-based Compensation (2020 - 2025)

Greenwich LifeSciences filings provide 6 years of Share-based Compensation readings, the most recent being $1.5 million for Q3 2025.

  • Quarterly Share-based Compensation rose 159.74% to $1.5 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $3.2 million through Sep 2025, up 32.68% year-over-year, with the annual reading at $306281.0 for FY2024, 87.12% down from the prior year.
  • Share-based Compensation hit $1.5 million in Q3 2025 for Greenwich LifeSciences, roughly flat from $1.5 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $1.8 million in Q1 2023 and bottomed at -$1.5 million in Q4 2024.
  • Average Share-based Compensation over 5 years is $511655.7, with a median of $594522.0 recorded in 2022.
  • Peak annual rise in Share-based Compensation hit 1015.18% in 2023, while the deepest fall reached 391.3% in 2023.
  • Greenwich LifeSciences' Share-based Compensation stood at $165429.0 in 2021, then soared by 259.38% to $594522.0 in 2022, then changed by 0.0% to $594522.0 in 2023, then crashed by 348.48% to -$1.5 million in 2024, then surged by 204.53% to $1.5 million in 2025.
  • Per Business Quant, the three most recent readings for GLSI's Share-based Compensation are $1.5 million (Q3 2025), $1.5 million (Q2 2025), and $1.5 million (Q1 2025).